A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Liver Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2010 by Hospital Authority, Hong Kong.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Schering-Plough
Information provided by:
Hospital Authority, Hong Kong
ClinicalTrials.gov Identifier:
NCT00563095
First received: November 21, 2007
Last updated: July 6, 2010
Last verified: July 2010

November 21, 2007
July 6, 2010
March 2004
Not Provided
regression of tumour size [ Time Frame: assessment every 6 months ]
Same as current
Complete list of historical versions of study NCT00563095 on ClinicalTrials.gov Archive Site
side effects [ Time Frame: every treatment given every 8 - 12 weeks ]
Same as current
Not Provided
Not Provided
 
A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Liver Cancer
A Comparative Study of the Efficacy of Transcatheter Arterial Chemoembolization (TACE) and Transcatheter Arterial Pegylated Interferon Embolization (TAIE) for Hepatocellular Carcinoma

Primary: To compare the efficacy of TACE and TAIE.

Secondary: To compare the side effects of TACE and TAIE.

The outcome measurements include survival benefit and tumour regression induced by the two therapies.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Carcinoma, Hepatocellular
  • Procedure: Transcatheter Arterial Chemoembolization (TACE)
  • Procedure: Transcatheter Arterial Pegylated Interferon Embolization (TAIE)
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
100
December 2008
Not Provided

Inclusion Criteria:

  • Confirmed hepatocellular carcinoma not suitable for surgery

Exclusion Criteria:

  • Portal vein thrombosis
  • Severe arteriovenous shunt
  • Bilirubin level > 50 umol/mL
  • Prothrombin time > 5 seconds
Both
18 Years and older
Not Provided
Contact: Man Fung Yuen, Prof (852) 2855 5311 mfyuen@hkucc.hku.hk
China
 
NCT00563095
EC 1942-02, HARECCTR0500039
Not Provided
Not Provided
Hospital Authority, Hong Kong
Schering-Plough
Principal Investigator: Man Fung Yuen, Prof Department of Medicine, Queen Mary Hospital/ The University of Hong Kong
Hospital Authority, Hong Kong
July 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP